FGFR2b protein overexpression, defined as 2+/3+ membrane staining, detected by immunohistochemistry (IHC), is prevalent in ~ 38% of advanced gastric/GEJ cancers2
The clinical impact of targeting FGFR2b in 1L gastric/GEJ cancers is being evaluated1,3
Amgen is committed to exploring the full potential of FGFR2b as an emerging biomarker
1L, first line; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; GEJ, gastroesophageal junction.
References: 1. Wainberg ZA, et al. Gastric Cancer. 2024;27:558-570. 2. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 3. Sato Y, et al. J Clin Med. 2023;12:4646.
References: 1. FPO 2. FPO 3. FPO
